Bortezomib Fresenius Kabi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0009 
B.II.b.3.a - Change in the manufacturing process of 
06/02/2024 
SmPC and PL 
the finished or intermediate product - Minor change 
in the manufacturing process 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
30/11/2023 
n/a 
PRAC Recommendation - maintenance 
02304 
bortezomib 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
IA/0007 
B.II.c.1.c - Change in the specification parameters 
30/06/2023 
n/a 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0006 
A.5.b - Administrative change - Change in the name 
13/04/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0005 
A.6 - Administrative change - Change in ATC 
28/07/2021 
18/07/2022 
SmPC 
ATC code update 
Code/ATC Vet Code 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
10/12/2020 
18/02/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02004 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/202004. 
IAIN/0004/G 
This was an application for a group of variations. 
06/11/2020 
18/02/2021 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0001/G 
This was an application for a group of variations. 
23/07/2020 
18/02/2021 
SmPC, Annex 
II, Labelling 
and PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/05/2020 
18/02/2021 
Annex II 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
